Denis Rodgerson

Director of Stem Cell Science at NeoStem, Inc. a company that specializes in the collection, processing and long term storage of adult stem cells for autulogous use (donor and recipient are the same). Dr. Rodgerson was the initial founder of NeoStem, a company whose objective is to become the leading provider of adult stem cell banking services for adults who wish to store their own adult stem cells for the future therapeutic use in the treatment of heart disease, diabetes, autoimmune disorders, cancer and other critical health problems.

Denis Rodgerson was born and received his education to the undergraduate level in Ireland. He studied at the University of Colorado, School of Medicine, where he was awarded a master’s and doctorate degree. He subsequently was appointed to a faculty position at the University of Colorado as Director of Analytical Toxicology and Head of Pediatric Laboratories. In 1974, Rodgerson accepted a position in the Department of Pathology at the University of California Los Angeles as Professor and Head of Clinical Chemistry and Toxicology. He later became Vice Chairman of the department and retired from active service at UCLA in 1999, remaining as Professor Emeritus. He is a fellow or member of many national and international professional organizations and has served on numerous committees at UCLA and the University of California system-wide.

Dr. Rodgerson has published more than 150 articles in the medical and scientific literature and is the inventor on several patents. He has been a consultant to many institutions and corporations, including NASA, National Bureau of Standards, Hewlett Packard, and Beckman Instruments.

Following retirement from UCLA he was a founder of StemCyte, Inc. Arcadia, California, an umbilical cord blood banking company, where he served as Chief Operating Officer and Senior Vice President until 2002. In 2002 Rodgerson founded and became the first President and Chief Executive Officer of NeoStem, Inc. In January 2006, NeoStem, Inc. was acquired by Phase III Medical, Inc., a public company (NYSE AMEX:NBS), and Dr. Rodgerson now has responsibility for the company’s stem cell science programs.

Related Links:
Ceres Living Website